Michael Metzger
Chief Executive Officer bei SYNDAX PHARMACEUTICALS, INC.
Vermögen: 4 Mio $ am 31.03.2024
Profil
Michael A.
Metzger is currently the Chief Executive Officer & Director at Syndax Pharmaceuticals, Inc. He is also a Director at Northern Westchester Hospital Association.
Previously, he served as the President, Chief Executive Officer & Director at Regado Biosciences, Inc. from 2014 to 2015.
He was an Independent Director at CTI BioPharma Corp.
from 2017 to 2023.
He also served as an Independent Director at Response Genetics, Inc. from 2010 to 2013.
In addition, he was the Managing Director at Mesa Partners, Inc. from 1997 to 2001.
He has also held positions as a Director at Tarveda Therapeutics, Inc., Head-Mergers & Acquisitions at Forest Laboratories, Inc., Vice President-Corporate Development at Traws Pharma, Inc., and Chief Operating Officer & Executive Vice President at Mersana Therapeutics, Inc. from 2011 to 2013.
He was the President, Chief Executive & Operating Officer at Tobira Therapeutics, Inc. Mr. Metzger completed his undergraduate degree at George Washington University and holds an MBA from The Leonard N Stern School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 08.03.2024 | 163 909 ( 0,19% ) | 4 Mio $ | 31.03.2024 |
Aktive Positionen von Michael Metzger
| Unternehmen | Position | Beginn |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Chief Executive Officer | 03.02.2022 |
Northern Westchester Hospital Association
 Northern Westchester Hospital Association Hospital/Nursing ManagementHealth Services Northern Westchester Hospital provides healthcare and medical services. It offers diagnostic, medical, surgical, obstetrical, pediatric and psychiatric care services. The firm also provides robotic, ambulatory, pediatric surgery, rehabilitation and anesthesiology services. The company was founded in 1916 and is headquartered in Mount Kisco, NY. | Director/Board Member | - |
Ehemalige bekannte Positionen von Michael Metzger
| Unternehmen | Position | Ende |
|---|---|---|
| CTI BIOPHARMA CORP. | Director/Board Member | 23.06.2023 |
| TOBIRA THERAPEUTICS INC | Chief Executive Officer | 04.05.2015 |
Regado Biosciences, Inc.
 Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Chief Executive Officer | 01.05.2015 |
| RESPONSE GENETICS, INC | Director/Board Member | - |
| MERSANA THERAPEUTICS, INC. | Chief Operating Officer | 01.11.2013 |
Ausbildung von Michael Metzger
| George Washington University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| TRAWS PHARMA, INC. | Health Technology |
| MERSANA THERAPEUTICS, INC. | Health Technology |
| RESPONSE GENETICS, INC | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
Mesa Partners, Inc.
 Mesa Partners, Inc. Investment ManagersFinance Mesa Partners, Inc. provides advisory services. It offers marketing, management, financial, government, and web business development services. The company was founded by Mitchell Sacks in 1972 and is headquartered in New York, NY. | Finance |
Northern Westchester Hospital Association
Northern Westchester Hospital Association Hospital/Nursing ManagementHealth Services Northern Westchester Hospital provides healthcare and medical services. It offers diagnostic, medical, surgical, obstetrical, pediatric and psychiatric care services. The firm also provides robotic, ambulatory, pediatric surgery, rehabilitation and anesthesiology services. The company was founded in 1916 and is headquartered in Mount Kisco, NY. | Health Services |
Tarveda Therapeutics, Inc.
 Tarveda Therapeutics, Inc. BiotechnologyHealth Technology Tarveda Therapeutics, Inc. discovers and develops cancer therapeutics and drugs. Its proprietary technology, assets and expertise are built around an integrative research and development process that brings together new-molecule drug discovery engine and patented nanoparticle engineering platform. The company was founded by Omid C. Farokhzad, Stephen J. Lippard and Robert S. Langer Jr., in 2011 and is headquartered in Watertown, MA. | Health Technology |
Tobira Therapeutics, Inc.
 Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on October 6, 2006 and is headquartered in Madison, NJ. | Health Technology |
